Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 5Y returns in the bottom 25% of the category. | - |
INDMoney rank | 3/8 | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 9 Years | 12 Years | ||
Fund Size | 1184 Cr | 3611 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.72% | 0.9% | ||
Exit Load | 0.25% | 0.5% | ||
Benchmark Index | Nifty Pharma TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.79%) Aurobindo Pharma Ltd (7.27%) Cipla Ltd (5.97%) Apollo Hospitals Enterprise Ltd (5.66%) Lupin Ltd (5.2%) | Sun Pharmaceuticals Industries Ltd (13.45%) Max Healthcare Institute Ltd Ordinary Shares (6.68%) Divi's Laboratories Ltd (6%) Cipla Ltd (4.79%) Lupin Ltd (4.72%) | ||
No of Sectors | 2 | 2 | ||
Top 3 Sectors | Health (97.56%) Basic Materials (2.44%) | Health (93.19%) Basic Materials (6.81%) | ||
Equity % | 95.76% | 96.96% | ||
Debt % | - | - | ||
P/E | 34.41 | 42.28 | ||
P/B | 4.98 | 5.85 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.99% | 3.84% | ||
3-Month Return | -3.75% | -1.2% | ||
6-Month Return | -8.15% | -3.17% | ||
1-Year Return | 17.07% | 20.71% | ||
3-Year Return | 20.02% | 23.52% | ||
5-Year Return | 23.79% | 26.35% |
Sharpe | 0.81 | 1.12 | ||
Alpha | 3.47 | 5.03 | ||
Beta | 0.95 | 0.85 | ||
Standard Deviation | 16.85 | 14.93 | ||
Information Ratio | 1.13 | 1 |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Meeta Shetty | Tanmaya Desai |